Prostate Carcinoma clinical trials

Explore recruiting prostate carcinoma clinical trials.

Recruiting prostate carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Prostate Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging followed by radical prostatectomy: A Prospective Phase II Pilot Study

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospective Phase II Pilot Study

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II randomized trial of Lu-PSMA and Stereotactic Radiotherapy versus Radiotherapy alone for oligometastatic prostate cancer (LUST)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration resistant prostate carcinoma

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)

Belgium, Germany, France, Italy, Poland, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Prostate Carcinoma trials by city

Prostate Carcinoma in Toronto Prostate Carcinoma in Vancouver Prostate Carcinoma in Montreal Prostate Carcinoma in Calgary Prostate Carcinoma in Edmonton Prostate Carcinoma in Ottawa Prostate Carcinoma in Winnipeg Prostate Carcinoma in Quebec City Prostate Carcinoma in Hamilton Prostate Carcinoma in Kitchener Prostate Carcinoma in London Prostate Carcinoma in Halifax Prostate Carcinoma in New York Prostate Carcinoma in Los Angeles Prostate Carcinoma in Chicago Prostate Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease